Ardelyx (ARDX) Projected to Post Quarterly Earnings on Thursday

Ardelyx (NASDAQ:ARDX) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect Ardelyx to post earnings of $0.02 per share and revenue of $118.0430 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Ardelyx Price Performance

ARDX opened at $7.26 on Thursday. Ardelyx has a 1 year low of $3.21 and a 1 year high of $8.40. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -31.56 and a beta of 0.57. The company has a current ratio of 4.41, a quick ratio of 4.11 and a debt-to-equity ratio of 1.31. The stock has a fifty day moving average price of $6.67 and a 200 day moving average price of $6.00.

Analyst Ratings Changes

Several research firms have weighed in on ARDX. Piper Sandler upgraded Ardelyx from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $10.00 to $16.00 in a research note on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ardelyx in a report on Wednesday, January 21st. Citigroup upped their price objective on Ardelyx from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Wedbush increased their target price on Ardelyx from $16.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Ardelyx in a research note on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $14.36.

Insider Activity

In other news, CEO Michael Raab sold 46,887 shares of the business’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $5.54, for a total transaction of $259,753.98. Following the completion of the transaction, the chief executive officer owned 1,455,363 shares of the company’s stock, valued at approximately $8,062,711.02. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mike Kelliher sold 5,560 shares of the stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $5.54, for a total transaction of $30,802.40. Following the sale, the insider owned 271,181 shares of the company’s stock, valued at approximately $1,502,342.74. This represents a 2.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 114,868 shares of company stock valued at $708,369. 4.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ardelyx

A number of hedge funds and other institutional investors have recently made changes to their positions in ARDX. Cerity Partners LLC boosted its holdings in Ardelyx by 5.3% in the fourth quarter. Cerity Partners LLC now owns 59,359 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,972 shares in the last quarter. Integrated Wealth Concepts LLC boosted its position in Ardelyx by 24.2% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 15,263 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 2,975 shares in the last quarter. E Fund Management Co. Ltd. raised its position in shares of Ardelyx by 8.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 40,023 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 3,255 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of Ardelyx by 1.3% during the third quarter. Alliancebernstein L.P. now owns 267,340 shares of the biopharmaceutical company’s stock valued at $1,473,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Osaic Holdings Inc. grew its stake in Ardelyx by 28.2% in the second quarter. Osaic Holdings Inc. now owns 16,854 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 3,709 shares during the period. Institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.